Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M3nMeWZ2dmO2aX;uJGF{e2G7 MUOwMlXDqM7:TR?= MW[yOEBp Mlfre4F1\XJ? NXrzdXhrdW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? M3XRbFI2OTJ|MEiy
Eca109 NYDUS|JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmwMlUwOi53L{Wg{txO Ml7WNlQwPDhxN{KgbC=> NE[wXG54[XSnch?= NXPjdpBtcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NX6yZZR1OjVzMkOwPFI>
Eca109 NWfKU5ZMTnWwY4Tpc44hSXO|YYm= Mnv6NE42yqEQvF2= M336PVYwOTJxMkSgbC=> M2\IepdifGW{ M37Gc4lvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= MlrPNlUyOjNyOEK=
Eca109 NWK5c5U1TnWwY4Tpc44hSXO|YYm= NELDboMxNjYEoN88US=> NVvZTJlQOjRiaB?= NIr3fmx4[XSnch?= MUHpcohq[mm2czDj[YxtKGmwdnHzbY9v MWSyOVEzOzB6Mh?=
Eca109 M{jjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmwMlXDqM7:TR?= NF7G[XMzPCCq M{CxSpdifGW{ Mn;vbY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> MX:yOVEzOzB6Mh?=
Eca109 MoLOSpVv[3Srb36gRZN{[Xl? NVvoSIZYOC53L{Gg{txO Mn3wNlQhcA>? M3XMTJdifGW{ NEexfGdl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{ M3zRU|I2OTJ|MEiy
SW1116  Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnZNE42NzFxMj:1JO69VQ>? NHz6fmg1QCCq Mlz6SG1UVw>? NWPGUFJ[\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? M2fBVlI1QDd2Mki2
LOVO MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLyTZIzOC53L{GvNk82KM7:TR?= M3qyT|Q5KGh? MnjWSG1UVw>? MWnlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NXjYcWtNOjR6N{SyPFY>
SW1116  M4rsVWZ2dmO2aX;uJGF{e2G7 MV2xNEDPxE1? M4mzflQ5KGh? M2iwWGROW09? NVTa[pRHcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MlLxNlQ5PzR{OE[=
LOVO NX2xWohUTnWwY4Tpc44hSXO|YYm= NUO3fmJ[OTBizszN MmPlOFghcA>? M3LMPGROW09? M4\W[Ilv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MonQNlQ5PzR{OE[=
SW1116  NX;aRoFlSXCxcITvd4l{KEG|c3H5 NWW3Rm1TOTBizszN NYqxSGxSPDhiaB?= NIrRfI1FVVOR NFq0NlZmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> M36yOlI1QDd2Mki2
LOVO NWrVcGU6SXCxcITvd4l{KEG|c3H5 NH6xeFcyOCEQvF2= M17HOFQ5KGh? NH:1fWdFVVOR MVvlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= MljQNlQ5PzR{OE[=
RPMI-8226 NHjCV|NCeG:ydH;zbZMhSXO|YYm= MkHJNU8zKM7:TR?= NVLj[VlTPDhxN{KvPVYhcA>? MUjEUXNQ NEHiSoRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3vMT|I1QDN|MUC4
OPM-2  MYrBdI9xfG:|aYOgRZN{[Xl? M2HaV|EwOiEQvF2= Mln5O|IwQTZxMUKwJIg> Ml6wSG1UVw>? MXPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3Thd|I1QDN|MUC4
JJN3  NF\OOWdCeG:ydH;zbZMhSXO|YYm= NEPNSmcxNjVxMTFOwG0> M1e5cFI1NzR6IHi= M{Hlb2ROW09? M1\YOolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M2jhV|I1QDN|MUC4
NCI-H929  NGTUeYlCeG:ydH;zbZMhSXO|YYm= M1OxelEwOiEQvF2= M{OwfFczNzl4L{GyNEBp MljsSG1UVw>? NUDQfJhTcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4jG[lI1QDN|MUC4
RPMI-8226 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MortNU8zKM7:TR?= MUOyOE81QC95MjDo MkHFSG1UVw>? NX7QXnk{[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NXX0ZWdXOjR6M{OxNFg>
OPM-2  M2PtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELhfWsyNzJizszN NFfzUVczPC92OD:3NkBp M1HjXWROW09? NEHpeJJi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= M4TEXlI1QDN|MUC4
JJN3  NY\iUId2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLX[ZIxNjVxMTFOwG0> M2DrSVI1NzR6L{eyJIg> MWPEUXNQ NULwUFZU[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MknCNlQ5OzNzMEi=
NCI-H929  MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ztVVEwOiEQvF2= NGDSWZkzPC92OD:3NkBp M3T4[2ROW09? NVS2Om82[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MkPMNlQ5OzNzMEi=
HeLa NYXScG5XU2mwYYPlJGF{e2G7 NEmyXY5McT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy NHf3NZUzPDd6MEC5PC=>
HeLa Mnv2T4lv[XOnIFHzd4F6 NYDnc4RlU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz MoPMNlQ4QDByOUi=
HeLa MlPHT4lv[XOnIFHzd4F6 NETVbI5McT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy MX[yOFc5ODB7OB?=
HeLa Mn7lT4lv[XOnIFHzd4F6 MYXLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz MUmyOFc5ODB7OB?=
NB4 M1u3e2Z2dmO2aX;uJGF{e2G7 MWKyMlUwPS95LkWvNVAh|ryP MnK1NlQhcA>? M1v4S2ROW09? Ml3JbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> MVeyOFQ5PDh5MB?=
CD4+ CD25− T  MWDGeY5kfGmxbjDBd5NigQ>? M3XpTVEwPSEQvF2= MXfy[YR2[2WVIHfsc4JidCCGTlGgcYV1cHmuYYTpc44> M{XNNVI1PDd4M{[w
BV-173 NG\3UYFCeG:ydH;zbZMhSXO|YYm= NEPlNm0xNjJ3L{CuOU8xNjd3L{Gg{txO NVm2ZY1EPDhxN{KvPVYhcA>? NG\zVZHDqFCEUx?= NI\0V|dqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MnTLNlQ1OjN4MUO=
ML-1 MXjBdI9xfG:|aYOgRZN{[Xl? NVnXcZo{OC5{NT:wMlUwOC55NT:xJO69VQ>? MYS0PE84Oi97NjDo MYlCpHBDWw>? NWHVZnZocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NFjLSYwzPDR{M{[xNy=>
HL-60 NH7NPYFCeG:ydH;zbZMhSXO|YYm= M3eyO|AvOjVxMD61M|AvPzVxMTFOwG0> NXLNVFhCPDhxN{KvPVYhcA>? NInWSHPDqFCEUx?= M{XGO4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M1jMZVI1PDJ|NkGz
KG-1a NUPhbIpwSXCxcITvd4l{KEG|c3H5 MYGwMlI2NzBwNT:wMlc2NzFizszN NVHkdVI1PDhxN{KvPVYhcA>? M1;nUOKhWEKV MWfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NEjqcIEzPDR{M{[xNy=>
BV-173 MnLXSpVv[3Srb36gRZN{[Xl? NFj5SmYzPTBxNUCwcm0> MVu0PEBp NHPuNlTDqFCEUx?= M2Tw[4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NX7tW3F5OjR2MkO2NVM>
CEM NYW2PWpITnWwY4Tpc44hSXO|YYm= NHLucHozPTBxNUCwcm0> Ml;IOFghcA>? MonrxsBRSlN? NVvQ[YN[cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MnHXNlQ1OjN4MUO=
HL-60 NWLUWFcyTnWwY4Tpc44hSXO|YYm= M3;XWlI2OC93MEDuUS=> NIj0TWM1QCCq MWNCpHBDWw>? NGjaV|NqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NWfNZlRQOjR2MkO2NVM>
ML-1 MWfGeY5kfGmxbjDBd5NigQ>? Mkf2NlUxNzVyMH7N Mm[xOFghcA>? MXlCpHBDWw>? NYfiPVc1cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NUj6dFA5OjR2MkO2NVM>
DLD-1 NXPkN5czTnWwY4Tpc44hSXO|YYm= M1TzW|I2OC93MEDuUS=> MljzOFghcA>? NYjnOIpbyqCSQmO= NH[2b3VldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NVi4WGJrOjR2MkO2NVM>
HCT-116 M4qzdmZ2dmO2aX;uJGF{e2G7 Mn;hNlUxNzVyMH7N MX20PEBp NGD5RZDDqFCEUx?= M4LLZ4RwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NU\sOmJrOjR2MkO2NVM>
U937-A/E-9/14/18  Ml7lRZBweHSxc3nzJGF{e2G7 MWqwMlAyNzBwMT:xM|ExKM7:TR?= NGm3b4Q1QCCq MkGwbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUmyOFMxODR3Nh?=
HT29 NVPzPVA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXpO|IhcA>? NIDle5hKSzVyPUG0NFDDuTF5OTFOwG0> MmDkNlQyPzJyNkG=
SW48 NXPSPGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XnPFczKGh? M1\pOGlEPTB;MUWuNuKyPi5{IN88US=> NVjHPJE{OjRzN{KwOlE>
HCT116 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TvdVczKGh? MVrJR|UxRTFwN9MxNE41KM7:TR?= Mlu0NlQyPzJyNkG=
HepG2 NFz5[nBHfW6ldHnvckBCe3OjeR?= NFjkepkxNjVxMTFOwG0> NVHSVWhoOjRiaB?= NI[zZ5BFVVOR M2jpbJVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MWWyOFE1Pjh5NB?=
LS174T M{nrT2Z2dmO2aX;uJGF{e2G7 NGrkTHExNjVxMTFOwG0> NGnPPYozPCCq Ml\NSG1UVw>? M1zQWIxm[WRidH:gZY4hcW6lcnXhd4Uhd2ZiT1PUUlIhdGW4ZXzz MVqyOFE1Pjh5NB?=
HepG2 Mnz0RZBweHSxc3nzJGF{e2G7 M2nGVlEwOTBxMUCwJO69VQ>? MWe3JIQ> M4HNOmROW09? MmW0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlP3NlQyPDZ6N{S=
LS174T M4HjVGFxd3C2b4Ppd{BCe3OjeR?= NXHWeVhNOS9zMD:xNFAh|ryP NHXGc244KGR? Mor6SG1UVw>? NVThZmlpcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NV;scpI1OjRzNE[4O|Q>
QBC-939 NIXibo1CeG:ydH;zbZMhSXO|YYm= M3v3flEwOTBxMUCwJO69VQ>? M33kbVch\A>? M1jESGROW09? MVnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{DpOFI1OTR4OEe0
U251 MkG0RZBweHSxc3nzJGF{e2G7 NHy0SooyNzFyL{GwNEDPxE1? NEH0Vno4KGR? MXnEUXNQ MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmKxNlQyPDZ6N{S=
HL-60 NHvEWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHJNUDPxE1? MY[0PEBp MXjpcoNz\WG|ZYOgS|IueGijc3WgZ4VtdCCocnHjeIlwdg>? MVyyOFAxODN{NB?=
MDA‑MB‑453 NFHJUHFHfW6ldHnvckBCe3OjeR?= NUGzUY1tOC5{L{Gg{txO NFPiPYs4OiCq NE\uSJJk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M{\B[lI{QDR2MkK4
HCC1569 MljISpVv[3Srb36gRZN{[Xl? NEnjdZMxNjJxMTFOwG0> M3q4R|czKGh? MUHjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M{XR[FI{QDR2MkK4
BT‑474 MkO5SpVv[3Srb36gRZN{[Xl? MX2wMlIwOSEQvF2= MUm3NkBp NGfBfFdk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MVWyN|g1PDJ{OB?=
AGS M{TTO2Fxd3C2b4Ppd{BCe3OjeR?= NELZd3U2NzFyL{KwM|UxKM7:TR?= NGfUPIg1QMLiaNMg M{TTPWROW09? MWTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> MojaNlM2QDJ5OES=
A549 MormRZBweHSxc3nzJGF{e2G7 Ml7lOU8yOC9{MD:1NEDPxE1? Mn3iOFjDqGkEoB?= M2DwN2ROW09? MkfubY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> NWrsbHZWOjN3OEK3PFQ>
AGS  NHLyT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonrOU8yOC9{MD:1NEDPxE1? MonaOFjDqGkEoB?= M1XVTWROW09? NGTHW41qdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> NHvFdW8zOzV6Mke4OC=>
Kasumi-1 NVHwS3o4SXCxcITvd4l{KEG|c3H5 NUTLTHdyOC53IN88US=> NHTrdnA1QMLiaNMg NVzhc293\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NFH1bGMzOzR7M{O0PC=>
OCI-AML3 MlzERZBweHSxc3nzJGF{e2G7 NHPlcZEzNjVizszN NUnNS29RPDkEoHlCpC=> NETlUItl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NID3Z3YzOzR7M{O0PC=>
MV4-11 MVjBdI9xfG:|aYOgRZN{[Xl? Mnm1Nk42KM7:TR?= M1r0elQ5yqCqwrC= M4fPN4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj M{HROlI{PDl|M{S4
NK  Ml;jR5l1d3SxeHn0fUBCe3OjeR?= NVnOeoltOC5yMj2yNEDPxE1? MX:1JIQ> M{Tnd4Rm[3KnYYPld{B1cGViY4n0c4x6fGmlIHHjeIl3cXS7IH;mJG5MKGOnbHzzJIF1KGmwdHXycYVlcWG2ZTDjc45k\W62cnH0bY9veyC{ZYP1cJRqdmdiaX6gZUBWNXOqYYDl[EBld3On4pETdoV{eG:wc3WgZ5VzfmV? NWqwNHE2OjN|MkiwPFg>
NK  NUPD[moxSXCxcITvd4l{KEG|c3H5 NWDJNpBkOC5yMj2yNEDPxE1? M3jOSlUh\A>? M4fBRYRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? NGHNT5EzOzN{OEC4PC=>
NK  MVPGeY5kfGmxbjDBd5NigQ>? NEXBRokxNjBzLUKwJO69VQ>? M4fvTlUh\A>? M4rZVoNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> Mn\FNlM{OjhyOEi=
MOLT4/DNR NGH0Nm1HfW6ldHnvckBCe3OjeR?= Mn;qOUDPxE1? MYK0JIQ> M1XQU5Jm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v NYS1d5FtOjNyNkC1O|A>
Jurkat/DOX MVPGeY5kfGmxbjDBd5NigQ>? MnLzOUDPxE1? M1XQTVQh\A>? NEjMeoVz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? NY\2fYtrOjNyNkC1O|A>
MOLT4/DNR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS1JO69VQ>? MkT2OEBl MWHy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 M1LPclI{ODZyNUew
Jurkat/DOX NVrEcIpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3ROUDPxE1? Mn22OEBl NInTd5Vz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 NU[xTZpmOjNyNkC1O|A>
ccRCC  M2TTN2Fxd3C2b4Ppd{BCe3OjeR?= MoXLNE4xOS1zMN88US=> MWe3NkBp NXruPZk{TE2VTx?= NWDGfGhpcGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= NUTJO2Z6OjJ6Mk[0Olc>
TNBC  MnXTRZBweHSxc3nzJGF{e2G7 MoHFNE4xOS1zMN88US=> MmfrO|IhcA>? MnHPSG1UVw>? NGn5cJpp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w M{jVe|IzQDJ4NE[3
A498 M1zBOGFxd3C2b4Ppd{BCe3OjeR?= MoPNNE4xOS1zMN88US=> MmC5O|IhcA>? MYXEUXNQ NWjEdWRUcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NXjQRVJXOjJ6Mk[0Olc>
KIJ265T NIT0PHdCeG:ydH;zbZMhSXO|YYm= MknVNE4xOS1zMN88US=> NIjXenM4OiCq M2OwNmROW09? Mn3wbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M{\lUlIzQDJ4NE[3
MDA-231 M1XM[mFxd3C2b4Ppd{BCe3OjeR?= M1LuSVAvODFvMUFOwG0> NGDqZWc4OiCq NIO0PVlFVVOR MnXCbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MYGyNlgzPjR4Nx?=
BT-20 NVPRWphiSXCxcITvd4l{KEG|c3H5 M3\xNlAvODFvMUFOwG0> NWTtcZhWPzJiaB?= NHP2[5VFVVOR MlnGbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MkLtNlI5OjZ2Nke=
U937 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\pOU0zOCEQvF2= NUL3Wnp5OjRxNEivO|IhcA>? MUnpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NGXNNJYzOjd4N{CyNS=>
HL60 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DiZVUuOjBizszN MXiyOE81QC95MjDo MXLpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MmO5NlI4PjdyMkG=
U937 NULLU2pySXCxcITvd4l{KEG|c3H5 NH\5WJgyPSEQvF2= Mk[xNlQwPDhxN{KgbC=> NUTaTm5ScW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NGfxdoczOjd4N{CyNS=>
HL60 MV\BdI9xfG:|aYOgRZN{[Xl? NFrGZYIyPSEQvF2= NHnNVGUzPC92OD:3NkBp Ml3rbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MV6yNlc3PzB{MR?=
LS411N  NHr4OWFCeG:ydH;zbZMhSXO|YYm= NVq0VWNpOC53IN88US=> NFrKdFQ4OiCq M2jH[olv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= NXnyXpRPOjJ2NkG2PVU>
MDA-MB-231 NI\2S2xCeG:ydH;zbZMhSXO|YYm= MUGxNEDPxE1? Ml\5OFghcA>? M1;oeZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2fURlIyQDh5Nkm3
MCF-7  MYjBdI9xfG:|aYOgRZN{[Xl? NVHrdZM6OTBizszN MWS0PEBp M1P1cpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV:yNVg5PzZ7Nx?=
A375 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzVNE42KM7:TR?= MU[xM|UwQCCm Mnz3bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M{\hSFIyPzl4NkKy
SKMEL1 NIq5TmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1uwd|AvPSEQvF2= Mn62NU82NzhiZB?= NGThcnZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NFvnRZczOTd7Nk[yNi=>
SKMEL3 NEPOWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMlUh|ryP MlzRNU82NzhiZB?= M13xNolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NEnGVIIzOTd7Nk[yNi=>
SKMEL28 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;qNE42KM7:TR?= MnHQNU82NzhiZB?= NYjxSXhycW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NUj1b3g2OjF5OU[2NlI>
MeWo M1vqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[wMlUh|ryP NULJR|NbOS93L{ig[C=> M33sbIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NX3wdVhoOjF5OU[2NlI>
B16 M4XWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[2Tpk4OC53IN88US=> MXexM|UwQCCm MmHRbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MVuyNVc6PjZ{Mh?=
Ly 1 NHW3NWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXiyOEBp M{PHNGlEPTB;Nz6zJO69VQ>? Ml\PNlE4PzJyNEm=
Ly 7 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;rZVI1KGh? M3PSdWlEPTB;MUCuO{DPxE1? MkjONlE4PzJyNEm=
Su-DHL6 M4P3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKyOEBp NED3XWRKSzVy78{eNlAh|ryP NX6yO2w{OjF5N{KwOFk>
Ly 10 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXKNlQhcA>? NVj1NpZuUUN3MP-8olIxKM7:TR?= M4m4NlIyPzd{MES5
RIVA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GzNlI1KGh? MmXyTWM2OO,:nkKwJO69VQ>? NU\LcIJ3OjF5N{KwOFk>
Su-DHL2 M1\0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGezR4YzPCCq NVG1eZNsUUN3MP-8olIxKM7:TR?= NVnJcXp4OjF5N{KwOFk>
Ly 1 NIj5V5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n2OVQ5KGh? NHfDeYFKSzVyPUCuN|Qh|ryP NF7hSmIzOTd5MkC0PS=>
Ly 7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXoXIc1QCCq MWjJR|UxRTBwMEK1JO69VQ>? MX[yNVc4OjB2OR?=
Su-DHL6 NHf6TGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HhU|Q5KGh? MljaTWM2OO,:nkKwJO69VQ>? MYCyNVc4OjB2OR?=
Ly 10 NXzsU5BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLtbZc1QCCq M3rReWlEPTB;MT64JO69VQ>? NHPWUJEzOTd5MkC0PS=>
RIVA NUe4T45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTNOFghcA>? NYPG[2xrUUN3MP-8olIxKM7:TR?= MnTiNlE4PzJyNEm=
Su-DHL2 NHTDTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu4PJA1QCCq NUPYOm9QUUN3ME2xO{41KM7:TR?= NWDPeHNIOjF5N{KwOFk>
Ly 1 NG\ITphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7ZO|IhcA>? MW\JR|UxRTBwMEGg{txO NUXoV3pWOjF5N{KwOFk>
Ly 7 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvsdnYzPzJiaB?= MVLJR|UxRTBwMEG4JO69VQ>? NGq3cGkzOTd5MkC0PS=>
Su-DHL6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmiyO|IhcA>? MV7JR|UxRTFwNjFOwG0> NV;pTYx7OjF5N{KwOFk>
Ly 10 NWCxUXpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7BO|IhcA>? MnvuTWM2OD1zLkKg{txO MoS5NlE4PzJyNEm=
RIVA MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TibFczKGh? MnPMTWM2OO,:nkKwJO69VQ>? M{XHWVIyPzd{MES5
Su-DHL2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofwO|IhcA>? NGPOWFNKSzVyPUGxMlIh|ryP NYDkdYNKOjF5N{KwOFk>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID